证券代码：688513 证券简称：苑东生物 公告编号：2025-035 成都苑东生物制药股份有限公司 第四届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 表决结果：9 票赞成，0 票反对，0 票弃权。同意票占本次董事会有效表决 票数的 100%，全票表决通过。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《关于调整 2024 年限制性股票激励计划授予价格的公告》。 （二）审议通过《关于作废 2024 年限制性股票激励计划部分限制性股票的 议案》 本议案已经公司第四届董事会薪酬与考核委员会审议通过。 1 成都苑东生物制药股份有限公司（以下称"公司"）第四届董事会第四次会议 于 2025 年 6 月 11 日以现场和通讯相结合的方式召开。会议通知已于 2025 年 6 月 6 日以专人送达、电话通知、电子邮件等形式送达全体董事。本次会议由董事 长王颖女士主持，应出席董事 9 名，实际出席董事 9 名。本次会议的召集、召开 和表决程序符合《 ...

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical and biotechnology industry, but it indicates a positive outlook on the innovation drug sector, particularly regarding the international expansion of domestic innovative drugs [3][4]. Core Insights - The report highlights the continuous rise in the enthusiasm for innovative drugs going overseas, with significant collaborations such as the $9 billion partnership between Bristol-Myers Squibb and BioNTech for the development of a PD-L1/VEGF dual antibody [3][4]. - It notes that the domestic innovative drug pipeline is becoming increasingly competitive on a global scale, with a long-term positive outlook for the internationalization of innovative drugs [3][4]. - The report also discusses the recent peak of COVID-19 cases in China, with a positivity rate of 23.8% reported at the end of May, indicating a need for continued monitoring [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.13% from June 3 to June 6, underperforming compared to the Wind All A index, which increased by 1.61% [9][10]. - Among sub-sectors, raw materials and blood products both saw a rise of 2.89%, while in vitro diagnostics increased by 2% [10]. - Notable stock performances included Yiming Pharmaceutical with a 33.1% increase, while *ST Longjin experienced a significant decline of 36.3% [12]. Industry News and Key Company Announcements - Significant events include the presentation of clinical data for IBI363 by Innovent Biologics at the ASCO conference, showing promising efficacy in treating advanced non-small cell lung cancer [12][13]. - Stone Pharmaceutical received approval for its adenosylcobalamin capsules, expanding its product line in the blood and nervous system treatment areas [13]. - CanSino Biologics announced the approval of a new indication for its PD-1/CTLA-4 inhibitor, filling a gap in the treatment of cervical cancer in China [13]. - The report also mentions various other approvals and collaborations among companies, indicating a vibrant and active industry landscape [13][14].

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical and biotechnology industry, but it indicates a positive outlook on the global competitiveness of domestic innovative drugs and the trend of innovative drugs going abroad [3][4]. Core Viewpoints - The innovative drug sector is experiencing a surge in overseas collaboration, highlighted by the partnership between Bristol-Myers Squibb and BioNTech to jointly develop a PD-L1/VEGF dual antibody with a total package worth $9 billion [3][4]. - The report notes that the recent ASCO conference showcased significant advancements in dual antibodies and ADCs, indicating a differentiated layout in early clinical stages for domestic innovative drugs [3][4]. - The report mentions a peak in the current COVID-19 wave, with a positivity rate of 23.8% reported at the end of May, which is higher than the entire year of 2024, although it has started to decline slightly [3][4]. Weekly Market Review - The pharmaceutical and biotechnology sector rose by 1.13% from June 3 to June 6, underperforming the Wind All A index, which increased by 1.61% [9][10]. - Among sub-sectors, raw materials and blood products both increased by 2.89%, while in vitro diagnostics rose by 2% [9][10]. - Notable stock performances included Yiming Pharmaceutical with a rise of 33.1%, Wanbangde at 32.6%, and Anglikang at 30.3%, while *ST Longjin fell by 36.3%, Huason Pharmaceutical by 12.4%, and Maipu Medical by 9.3% [12][10]. Industry News and Key Company Announcements - On June 4, Innovent Biologics reported promising Phase I clinical data for IBI363 in treating advanced non-small cell lung cancer at the ASCO annual meeting [12][13]. - On June 6, CSPC announced that its adenosylcobalamin capsules received drug registration approval from the National Medical Products Administration [13][14]. - On June 5, CanSino Biologics announced the approval of a new indication for its PD-1/CTLA-4 inhibitor in first-line treatment for cervical cancer [13][14]. - On June 2, Bristol-Myers Squibb and BioNTech announced a collaboration to develop the PD-L1/VEGF dual antibody BNT327, with a significant financial commitment involved [13][14].

Group 1 - The company Chengdu Yuandong Pharmaceutical Co., Ltd. has been awarded the China Patent Excellence Award for its invention patent "A Fumaric Acid Bisoprolol I Crystal Form and Its Preparation Method" related to Fumaric Acid Bisoprolol Tablets (Su Nuo Le) [1][2] - The China Patent Award is co-hosted by the National Intellectual Property Administration and the World Intellectual Property Organization, and it is the only government award in China specifically for granting patent rights for inventions [1] - In the 25th China Patent Award, a total of 607 China Patent Excellence Awards were granted, along with other categories such as gold and silver awards for patents and designs [1] Group 2 - The award signifies recognition of the company's efforts in innovative drug research and intellectual property protection, highlighting the technological advancement, innovation, and clinical value of the drug [3] - As of December 31, 2024, the company has applied for a total of 425 patents, including 408 invention patents, with 156 patents authorized, including 142 invention patents [3] - The company aims to continue focusing on innovation and intellectual property management to develop more high-quality innovative drugs, contributing to the health of the Chinese population and benefiting global patients [3]

证券代码：688513 证券简称：苑东生物 公告编号：2025-034 一、本次获奖情况概述 中国专利奖由国家知识产权局与世界知识产权组织共同主办，是中国唯一 专门针对授予专利权的发明创造给予奖励的政府部门奖，在国内外具有广泛影 响力。根据《中国专利奖评奖办法》规定，经国务院有关部门知识产权工作管 理机构、地方知识产权局、有关全国性行业协会，以及中国科学院院士和中国 工程院院士等推荐，中国专利奖评审委员会评审，并向社会公示，第二十五届 中国专利奖共授奖中国专利金奖 30 项，中国外观设计金奖 10 项，中国专利银 奖 60 项，中国外观设计银奖 15 项，中国专利优秀奖 607 项，中国外观设计优 秀奖 47 项，并对广东省、上海市的部分知识产权局和院士分别授予中国专利奖 最佳组织奖、优秀组织奖和最佳推荐奖。 本次公司富马酸比索洛尔片（苏莱乐 ®）的发明专利"一种富马酸比索洛尔 I 晶型及其制备方法"（专利号：ZL201610604361.6）荣获中国专利优秀奖。 二、对公司的影响及风险提示 专利是药企的核心资产之一，也是保护创新成果、维持市场竞争优势的关 键。本次公司富马酸比索洛尔片的发明专利获得第二十五届 ...

Investment Rating - The industry investment rating is "Overweight" [2] Core Insights - The report highlights the ongoing active research in life sciences and the global wave of biotechnology revolution, which is accelerating integration into economic and social development, providing new solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [5][12]. Summary by Sections 1. Industry Market Performance - The synthetic biology sector saw an increase of 1.13% in the week of May 26 to May 30, 2025, outperforming the Shanghai Composite Index by 1.16% and the ChiNext Index by 2.53% [6][20]. 2. Company Business Progress - Shanghai Puranwei and the Shanghai Academy of Agricultural Sciences signed a strategic cooperation agreement to develop mycelium leather technology, aiming to create a new type of biological material to replace traditional leather [26]. - Angel Yeast announced a 230 million yuan investment in a project focused on serum-free cell culture medium technology, marking its entry into the synthetic biology sector [26]. - Xiangsheng Technology unveiled its Shanghai product headquarters, focusing on the large-scale application of bio-based materials like FDCA and PEF [27]. 3. Industry Financing Tracking - The report notes an acceleration in financing for synthetic biology companies, with nearly a hundred companies completing new financing rounds since the beginning of 2025 [37]. - Haobo Pharmaceutical completed a $50 million B+ round of financing to advance its antisense oligonucleotide drug AHB-137 for chronic hepatitis B [37]. - Swiss biotechnology company GlycoEra raised $130 million in a B round to develop its IgG4-targeting protein degradation agents [37].

成都苑东生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，现将相关 情况公告如下： 一、药品基本情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688513 证券简称：苑东生物 公告编号：2025-032 成都苑东生物制药股份有限公司 关于自愿披露阿昔替尼片获得药品注册证书的公告 药品名称：阿昔替尼片 剂型：片剂 规格：5mg 注册分类：化学药品 4 类 药品有效期：18 个月 上市许可持有人：成都苑东生物制药股份有限公司 生产企业：成都苑东生物制药股份有限公司 药品注册标准编号：YBH33092024 受理号：CYHS2303471 证书编号：2025S01566 药品批准文号：国药准字 H20254331 1 生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可 生产销售。 二、药品的其他相关情况 阿昔替尼片活性成份为阿昔替尼，适应症：用于既往接受过一种酪氨酸激 酶抑制剂或细胞因子治疗失败的进展期肾细胞癌（RCC） ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-033 成都苑东生物制药股份有限公司 关于自愿披露阿帕他胺片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，现将相关 情况公告如下： 一、药品基本情况 药品批准文号：国药准字 H20254353 药品名称：阿帕他胺片 剂型：片剂 规格：60mg 注册分类：化学药品 4 类 药品有效期：18 个月 上市许可持有人：成都苑东生物制药股份有限公司 生产企业：成都苑东生物制药股份有限公司 药品注册标准编号：YBH07062025 受理号：CYHS2400138 证书编号：2025S01588 审批结论： 根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及 1 生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可 生产 ...

Group 1 - Weijie Chuangxin's shareholders plan to reduce their holdings by up to 3% of the company's shares, totaling no more than 12.9094 million shares [1] - Yuandong Biological received a drug registration certificate for Oxycodone tablets, which are used for short-term relief of anxiety and other conditions [1] - Jiahua Food's shareholder Ningbo Helix plans to reduce its holdings by up to 1.15% of the company's shares, totaling no more than 5.208 million shares [1] - Helin Micro-Nano's controlling shareholder plans to reduce its holdings by up to 1.5% of the company's shares, totaling no more than 1.7526 million shares [1] Group 2 - Huamao Technology plans to acquire 57.84% of Fuchuang Youyue's equity, aiming to hold 100% after the transaction [2] - Bluet Optical's shareholders plan to collectively reduce their holdings by up to 0.85% of the company's shares [3] - Nanhua Futures' H-share listing remains uncertain, pending approvals from various regulatory bodies [3] - Milkway plans to acquire 30% of Tianjin Wozhe for 142 million yuan to enhance logistics services [3] - Aisheng plans to invest approximately 750 million yuan in a wind power project in Linyi [3] Group 3 - Lier Chemical's shareholder Zhongtong Investment plans to reduce its holdings by up to 3% of the company's shares, totaling no more than 24.0131 million shares [5] - Agricultural Products received approval from the Shenzhen Stock Exchange for a specific stock issuance [5] - Huanrui Century's shareholder Qingyou Ruihe's 2.34% stake will be subject to judicial enforcement [5] Group 4 - Leao Planning's shareholders plan to transfer a total of 5.1% of the company's shares through an agreement [6] - Honghe Technology is planning a change in control, leading to a temporary suspension of its stock [7] - Zhongke Electric plans to invest up to 8 billion yuan in an integrated lithium-ion battery anode materials project in Oman [7]

证券代码：688513 证券简称：苑东生物 公告编号：2025-030 成都苑东生物制药股份有限公司 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否涉及差异化分红送转：是 ? 每股分配比例 每股现金红利0.43元 ? 相关日期 股权登记日 除权（息）日 现金红利发放日 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（成 都苑东生物制药股份有限公司回购专用证券账户除外）。 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海证券交易 所上市公司自律监管指引第 7 号--回购股份》等相关规定，上市公司回购专用账户 中的股份，不享有股东大会表决权、利润分配、公积金转增股本、认购新股和可 转换公司债券等权利，不得质押和出借。 （1）差异化分红方案 根据上海证券交易 ...